ArticleApoptosis : an international journal on programmed cell death2026
TRIM21 inhibition alleviates acute kidney injury by promoting INTS3-associated DNA damage repair.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Acute kidney injury (AKI) is a common and severe clinical complication with limited treatment options. TRIM21, an E3 ubiquitin ligase, was previously shown to be upregulated in ischemia/reperfusion (I/R)-induced AKI. This study further revealed its role in DNA damage repair. Here, we demonstrated that TRIM21 expression is elevated in human kidney biopsies, murine AKI models, and injured renal tubular epithelial cells (TECs), in parallel with increased DNA double-strand breaks (DSBs). TRIM21 knockout attenuated renal injury, improved renal function, and decreased TECs apoptosis. Mechanistically, TRIM21 was found to bind to INTS3 and facilitate its proteasomal degradation, suppressing DNA repair and promoting apoptosis. INTS3 overexpression alleviated cisplatin-induced DNA damage and apoptosis in TECs. Through virtual screening and activity evaluation, SB33-0223 was identified as a small-molecule inhibitor targeting the C-terminal PRYSPRY domain of the TRIM21 protein. By blocking the recruitment of antibody-bound substrates, SB33-0223 effectively prevents TRIM21-mediated ubiquitination and degradation of INTS3, thereby enhancing INTS3 stability and reducing DNA damage in vitro and in vivo. Our study discovered SB33-0223 as an inhibitor of TRIM21 for the first time, highlighting the TRIM21/INTS3 axis as a critical regulator of DNA repair in AKI, supporting SB33-0223 as a promising lead for targeted therapeutic intervention.
Indexed as
Identifiers
42671466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.